2Department of Surgical Oncology, Sir H.N. Reliance Foundation Hospital and Research Centre, Mumbai-India DOI : 10.5505/tjo.2024.4423 OBJECTIVE
This study explores ultra-hypofractionated breast radiation therapy in 110 Stage I-III breast cancer patients, focusing on dosimetry, toxicity, overall survival (OS), and disease-free survival (DFS).
METHODS
Conducted from May 2020 to May 2023, the study enrolled patients undergoing ultra-hypofractionated
adjuvant radiation therapy post-surgery. Dosimetric parameters were recorded, and toxicity was assessed
using SPSS software. Patients underwent either Modified Radical Mastectomy (MRM) or Breast Conservation
Surgery (BCS), receiving 26 Gy in 5 fractions over 1 week or a simultaneous integrated boost (SIB)
of 6 Gy after BCS. Deep Inspiratory Breath Hold and Surface Guided Radiation Therapy were employed.
RESULTS
The study enrolled 110 patients. Toxicity at the end of treatment included 89% Grade 1 skin toxicity and
18.18% Grade 1 dysphagia, with minimal Grade 2 skin toxicity at the last follow-up. Dosimetric analysis confirmed
adequate coverage within organs-at-risk constraints. The 2-year OS was 95.6%, and DFS was 92.7%.
CONCLUSION
The study shows that ultra-hypofractionated breast radiation therapy is feasible and effective, achieving
a favorable overall survival of 95.6%. Dosimetric constraints were met with good acceptance. The retrospective
nature and absence of a control group present limitations, urging further exploration.